Search research articles

Search research articles

Related Experiment Videos

Appropriate specifications at the IND stage

¹Quality, IDEC Pharmaceuticals Corporation, San Diego, CA, USA.

Developments in Biological Standardization

|January 1, 1997

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Appropriate specifications at the IND stage.

PDA journal of pharmaceutical science and technology·1997

Same author

Development and shelf-life determination of recombinant human granulocyte--macrophage colony-stimulating factor (LEUKINE, GM-CSF).

Pharmaceutical biotechnology·1996

Same author

Role of quality control in validation of biopharmaceutical processes: case example of clean-in-place (CIP) procedure for a bioreactor.

PDA journal of pharmaceutical science and technology·1994

Same author

Development and shelf-life determination of recombinant interleukin-2 (proleukin).

Pharmaceutical biotechnology·1993

Same author

Overview of the stability and handling of recombinant protein drugs.

Journal of parenteral science and technology : a publication of the Parenteral Drug Association·1989

Same author

The long-term stability of recombinant (serine-17) human interferon-beta.

Journal of interferon research·1988

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Setting early-stage biopharmaceutical product specifications requires careful consideration of available data. This discussion explores practical approaches to establishing scientifically sound specifications during Investigational New Drug (IND) trials.

Area of Science:

Biopharmaceutical Development
Regulatory Science
Quality Control

Background:

Biopharmaceutical product specifications must be scientifically sound and appropriate.
Early clinical development (Investigational New Drug - IND trials) presents challenges in establishing robust specifications due to limited data.
Industry practices may lead to excessive testing and pressure for unrealistic early specifications.

Purpose of the Study:

To discuss practical strategies for setting product specifications for biopharmaceuticals at the IND stage.
To address the challenges of data limitations and regulatory pressures in early-stage specification setting.
To propose a balanced approach to specification setting that avoids premature or overly stringent requirements.

Main Methods:

Related Experiment Videos

Review of current industry practices and challenges in setting biopharmaceutical specifications.

Discussion of the implications of data availability during early clinical development.

Analysis of the influence of regulatory expectations and corporate culture on specification setting.

Main Results:

Limited data at the IND stage complicates the establishment of scientifically sound specifications.
An overemphasis on testing and a "checklist" approach can lead to unnecessary complexity.
Setting overly tight specifications early can create future challenges in justification for adjustments.

Conclusions:

Practical product specifications for biopharmaceuticals should be established with consideration for data evolution.
A phased approach to specification setting, informed by accumulating data, is recommended.
Balancing scientific rigor with practical considerations is crucial for successful early-stage biopharmaceutical development.